Discover the materials available to empower your patients through their TZIELD journey. Access comprehensive resources that help patients understand their Type 1 risk, what TZIELD treatment involves, and how to navigate their care pathway with confidence.
Patient Website
This patient website (www.uk-tzield.com) is the go-to digital platform for your patients to explore their treatment, what to expect, and find additional resources and links.
Risk Minimisation Materials
Patient Guide
This Patient Guide has been developed for your patients, following their TZIELD prescription. Your patients should read this material before treatment, as it contains key safety information about their treatment with Tzield.
Patient Information Leaflet
This Patient Information Leaflet contains key safety information about their treatment with Tzield. You can share this material together with Patient Guide.
Paediatric patients and caregivers
Patient Handbook (Paediatric)
This handbook contains age specific messaging for individuals aged 8-13, to guide them through their end-to-end TZIELD treatment journey.
Download Patient handbookPatient Wallet (Paediatric)
This folder includes a 14-day infusion tracker, useful support website links and can be used by paediatric patients or caregivers to store any TZIELD associated documents they receive during their treatment.
Download Patient walletAdult Patients
Patient Wallet (Adults)
This folder includes a 14-day infusion tracker, useful support website links and can be used by patients to store any TZIELD associated documents they receive during their treatment.
Download Patient handbookPatient Handbook (Adults)
This handbook contains information to guide your patient through their end-to-end TZIELD treatment journey.
Download Patient walletWant printed copies of these materials?
Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.1
RMMs, risk minimisation materials; PIL, patient information leaflet.
- TZIELD® (teplizumab) UK Summary of Product Characteristics. 2025.
MAT-XU-2600466 (v1.0) | March 2026